Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

465
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
465
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Coagulation01:09

Coagulation

11.9K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
11.9K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.3K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

10.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leukoaraiosis and acute ischemic stroke: 90-day clinical outcome following endovascular recanalization, with proposed "L-ASPECTS".

Journal of neurointerventional surgery·2020
Same author

Association of local anesthesia versus conscious sedation with functional outcome of acute ischemic stroke patients undergoing embolectomy.

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences·2020
Same author

Recurrent cryptogenic stroke: A potential role for an artificial intelligence-enabled electrocardiogram?

HeartRhythm case reports·2020
Same author

Update on Treatment of Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2020
Same author

Aneurysmal subarachnoid hemorrhage: long-term trends in incidence and survival in Olmsted County, Minnesota.

Journal of neurosurgery·2020
Same author

Sudden Cardiac Arrest Survivorship: A Scientific Statement From the American Heart Association.

Circulation·2020

Related Experiment Video

Updated: Mar 28, 2026

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K

Periprocedural warfarin reversal with prothrombin complex concentrate.

Meera Sridharan1, Waldemar E Wysokinski2, Rajiv Pruthi3

  • 1Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.

Thrombosis Research
|December 15, 2015
PubMed
Summary
This summary is machine-generated.

Three factor prothrombin complex concentrate (PCC) effectively reverses warfarin

Keywords:
AnticoagulantsBleedingProthrombin complex concentrate (PCC)ThrombosisWarfarin

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.1K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.4K

Related Experiment Videos

Last Updated: Mar 28, 2026

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.1K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.4K

Area of Science:

  • Cardiology
  • Hematology
  • Medical Procedures

Background:

  • 10% of anticoagulated patients need procedures annually.
  • 1 in 10 procedures are emergent, requiring rapid anticoagulation reversal.
  • 3-factor prothrombin complex concentrate (PCC) is used for warfarin reversal.

Purpose of the Study:

  • To determine the safety and efficacy of 3-factor PCC for periprocedural anticoagulation reversal.
  • To evaluate outcomes in patients undergoing invasive procedures or experiencing major bleeding.
  • To assess rates of INR normalization, hemorrhage, thromboembolism, and mortality.

Main Methods:

  • Retrospective analysis of patients receiving 3-factor PCC for warfarin reversal.
  • Patients were categorized into peri-procedure or major bleeding groups.
  • Primary endpoints: INR <1.5, major hemorrhage, thromboembolism, and death within 40 days.

Main Results:

  • 51% of peri-procedure patients achieved INR <1.5 within 2.5 hours.
  • Major bleeding (13%), thromboembolism (13%), and mortality (15%) were high in the peri-procedure group.
  • 75% of major bleeding patients achieved INR <1.5 within 4 hours, with high thromboembolism (21%) and mortality (16%) rates.

Conclusions:

  • 3-factor PCC promptly reverses INR but is associated with high rates of thromboembolic and fatal complications.
  • Judicious use of PCC is recommended in high-risk populations undergoing urgent procedures.
  • Restarting warfarin therapy did not impact complication rates, but mortality was higher in non-warfarin restart patients.